Trevi Therapeutics, Inc. TRVI Income taxes at U.S. statutory rate of 21%
Income taxes at U.S. statutory rate of 21% at other companies
Other financials
Where this comes from
Reported directly by Trevi Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate.
The official record: Trevi Therapeutics, Inc.’s 10-K, filed March 17, 2026, on SEC EDGAR. View the filing →
Ask your AI about Trevi Therapeutics, Inc.'s income taxes at u.s. statutory rate of 21%.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Trevi Therapeutics, Inc.'s income taxes at U.S. statutory rate of 21%?
- Trevi Therapeutics, Inc. (TRVI) reported income taxes at U.S. statutory rate of 21% of 21% in Q4 2025.
- How has Trevi Therapeutics, Inc.'s income taxes at U.S. statutory rate of 21% changed year-over-year?
- Trevi Therapeutics, Inc.'s income taxes at U.S. statutory rate of 21% decreased by 0.0% year-over-year, from 21% to 21%.
- What does income taxes at U.S. statutory rate of 21% mean?
- Quantifies the impact of the federal statutory tax rate on the company's income tax provision, expressed as a monetary amount. This metric is used to reconcile the difference between the statutory rate and the actual effective tax rate reported in the financial statements. It highlights the primary tax rate applied to the company's earnings before accounting for specific tax benefits or expenses.